Your Pet Care Got Worse On Purpose

You have been to one of these clinics. Maybe it was a Banfield tucked into the corner of a PetSmart, or a VCA with a bright clean logo. Maybe even a place with a warm local name like ‘Lakeside Animal Hospital’. At some point the visits started changing. The prices climbed faster than you remembered. The vet you trusted left without much explanation. A routine appointment came back with a recommendation for bloodwork and a dental cleaning and a bag of prescription food all at once. You paid it, because of course you paid it.

What is never clear when sitting in the lobby is who owns the building. The largest provider of veterinary care on the planet is Mars, the company that makes Snickers and M&Ms and Pedigree. It also runs more than 2,000 clinics in the United States under names like Banfield, VCA and BluePearl.

A decade ago, fewer than 10% of American veterinary practices were corporate-owned. The buying has concentrated almost entirely on the clinics that treat dogs and cats, while equine and farm-animal medicine have been largely left alone. In that companion-animal world corporate consolidators now own roughly a quarter of primary care clinics and about three-quarters of specialty and emergency hospitals, together accounting for around half of all veterinary revenue in the country. The neighborhood vet, as a category, is being absorbed by a small number of conglomerates and private equity firms that would prefer you not notice.

There are two kinds of buyer.

The first buys clinics and keeps them. Mars is the primary example here. It took a stake in Banfield in 1994 and bought the chain outright in 2007. It then acquired the specialty and emergency group BluePearl in 2015, and in 2017 paid roughly $9 billion to take VCA private. A single deal that added around 800 hospitals and handed Mars control of Antech, the lab that runs diagnostics for much of the country (Fortune; FTC). Mars does not flip what it buys. It accumulates.

The second operates on a clock: buy a platform, borrow against it, fold in smaller practices, squeeze costs, and sell in three to seven years at a multiple of earnings. KKR's PetVet Care Centers has grown from about 125 hospitals in 2017 to more than 450, financed in 2023 by a $2.3 billion loan the clinics themselves now have to service. JAB Holding, the family office behind Krispy Kreme and Panera, built a rival empire through National Veterinary Associates and was ordered by the Federal Trade Commission to divest clinics twice in 2022 alone.

Either way, the outcome does not favor the pet owner. Whether a buyer means to hold a clinic forever or sell it in five years, it is run as a financial instrument first and a medical practice second. The landlord still sets margin targets, and the flipper still has to make the debt payments. In both cases the care your animal gets and the price you pay for it were settled in a meeting you weren't in, by people who will never meet your dog.

The reason this particular corner of medicine attracted billions of dollars in acquisition money is due to the structure of the business. Veterinary care is paid in cash at the point of service, with none of the insurer-reimbursement lag that complicates human medicine. Demand is close to inelastic, because the person holding the leash will find the money when the alternative is watching a family member suffer. And the liability is minimal, since pets are legally classified as property, which means a botched outcome that would trigger a malpractice catastrophe in human medicine produces, at most, a claim for the replacement value of a dog.

The practices themselves are profitable and, until recently, cheap. Veterinary valuation brokers (the firms that exist to sell clinics to consolidators) describe the economics with startling candor. A healthy independent clinic runs an operating margin somewhere in the low-to-mid teens. Brokers advise sellers that anything under 10% is a red flag for buyers, while a margin of 18% or higher is what attracts a premium price. One brokerage refers to practices outright as "flippable houses," properties a buyer can pick up, tidy, and resell at a profit. The gap between what an independent vet is willing to earn and what a corporate owner intends to extract is the entire engine of the story, and closing that gap is done in the exam room, on the invoice and in the staffing schedule.

The last ingredient was supply. American veterinary medicine was, until about fifteen years ago, a cottage industry of some thirty thousand independent practices, a large share of them owned by veterinarians old enough to be thinking about retirement. A consolidator can offer a retiring owner two, five, sometimes ten times what the practice would fetch from the younger associate who has worked there for years and assumed they would one day buy in. The associate, carrying student debt that now routinely runs past two hundred thousand dollars, cannot come close to matching that offer. So the practice sells, the name on the door stays the same and the new owner is a holding company in another state.

Eighteen states prohibit anyone who is not a licensed veterinarian from owning a veterinary practice, on the old and sound principle that a person whose job is to generate returns should not be making medical decisions or directing the people who do. The consolidators worked around this with a structure borrowed from human healthcare, and they did it in the open, with law firms advertising the method as a service.

It works like this. The corporation creates a management services organization (MSO) which owns everything about the practice that is not, strictly, the practice of medicine: the building, the equipment, the inventory, the staff, the scheduling, the billing, and the bank account. A veterinarian, frequently one chosen by and friendly to the corporation, owns the medical entity on paper and is said to control clinical decisions. The two sign a management agreement under which the vet-owned entity pays a fee to the MSO. That fee is calibrated to route essentially all of the profit back to the corporation.

The American Economic Liberties Project, which has drafted model legislation to ban the structure, concluded that these arrangements render the state ownership laws "all but meaningless." This is not a loophole someone stumbled into. Veterinary mergers-and-acquisitions attorneys market MSO setups to buyers as the standard tool for entering states where direct ownership is illegal, and the trade press explains the mechanics in how-to articles aimed squarely at the people doing the buying.

The clearest measure of the change is the price. Veterinary service prices in the United States have risen more than 60% over the past decade, far outpacing inflation.

Some of that increase buys genuinely better medicine: the MRIs and CT scanners and oncology that can extend an animal's life in ways that were impossible a generation ago. Some of it pays technicians the raises they were long owed. But a meaningful share is just new ownership deciding the practice would charge more.

A veterinary-telehealth executive who studied regional pricing found that increases tended to land "immediately after the sale to a private-equity-owned group," and one emergency vet described prices rising 20% in a single year.

The mechanism by which a spreadsheet target becomes your invoice is the way these chains pay and pressure their veterinarians. Vets at corporate practices are frequently paid on production (a percentage of the revenue they personally generate) which quietly turns every recommendation into a transaction with a stake for the person making it. Veterinarians told the New York Times that corporate managers pushed them to see more animals and order more tests and sell more wellness plans and food. One vet recounted quitting after she was told her "cost per client" was too low. A peer-reviewed study in 2025 found that veterinarians in corporate practices reported significantly more pressure to generate revenue and to see more clients per shift than their peers in independent practice.

The pressure reaches past the clinic into the businesses it buys from. Mars owns Antech, one of the two labs that dominate veterinary diagnostics in North America. So when a Mars veterinarian orders bloodwork, the sample goes to a Mars lab. JAB runs the same play across more of the chain. It owns hundreds of clinics, a string of diagnostic labs, and a pet-insurance operation covering millions of animals.

The most revealing artifact of the whole model is Banfield's Optimum Wellness Plan, the monthly-payment package Mars sells inside PetSmart stores as a way to save on routine care. The plan is a twelve-month contract that renews automatically, and the advertised savings are real enough on paper, but the structure is built so that leaving is expensive. The valuable services, the dental cleaning and the vaccines, are loaded into the front of the year, so a customer who cancels partway through is told they have already consumed more value than they have paid in and must settle the difference. Cancellation without penalty is only possible during a narrow window before the renewal date.

The complaint records at the Better Business Bureau and ConsumerAffairs run for pages, and a striking number follow the same script: a pet dies, the grieving owner calls to cancel, and a representative explains that the contract is still owed. Owners report being billed $151, or $250, or in one case $719 that was turned over to a collections agency, for wellness plans attached to animals that were already dead. The practice is old enough to have produced a federal class action back in 2013, which alleged that Banfield's upselling wiped out the very discounts the plan advertised. Mars has been collecting on dead pets for more than a decade, and the plan is still for sale.

The squeeze reaches the veterinarians too, and it lands on a profession that was already struggling. New graduates leave veterinary school owing around $150,000 against starting salaries that do not come close to covering it. They walk into a workplace where, more and more, the protocols and the prices and the pace are set by corporate. They lose the clinical autonomy that drew them to the work, and they carry the moral weight of recommending care that families cannot afford while having no legal standing to treat an animal whose owner says no. The profession's suicide rate runs well above the general population's. While corporate ownership did not create that crisis, the loss of control and the constant revenue pressure aggravate the conditions that drive it.

Under Lina Khan, The Federal Trade Commission treated veterinary roll-ups as a genuine antitrust problem and forced divestitures in the deals large enough to notice. For instance, it ordered Mars to sell a dozen clinics as a condition of the VCA purchase and also forced JAB to divest clinics twice in 2022 as it swallowed SAGE and Ethos. The agency even imposed a standing requirement that JAB give advance notice before buying any specialty or emergency clinic within twenty-five miles of one it already owned.

The trouble is that the great majority of acquisitions are too small to trigger federal review at all, and a roll-up assembled from dozens of individually unremarkable purchases can reach regional dominance without a single deal ever crossing the threshold that would land it on the Commission's desk.

So the fight has moved to the states, where it is mostly losing. The American Economic Liberties Project has published a model bill, the Save Our Pets Act, that would ban the MSO workaround outright and require disclosure and review of veterinary transactions. A version of the transaction-review idea was introduced in New York in late 2025. But as of early 2026 more of these state bills have died than passed, and the federal posture under a new administration is an open question.

There is no cavalry coming over the hill. What exists is a slow and underfunded effort to make ownership visible, which is worth supporting precisely because visibility is the one thing the model depends on you not having.

What is within reach of any pet owner is smaller, though it is not nothing. You can learn who owns your clinic before the day you urgently need it. Ownership is rarely posted on the door, so ask at the front desk whether the practice is independent or part of a group, and notice how readily they answer. You can look the practice up on your state veterinary board or business registry, where an out-of-state parent or a separate management company is often the giveaway. You can run the clinic's name against the major portfolios: Mars (Banfield, VCA, BluePearl, AniCura), JAB's National Veterinary Associates, KKR's PetVet, and groups like Thrive, VetCor, and the combined Mission and Southern operation, which hold hundreds of clinics between them.

The signals that matter most are harder to check from a website. Ask how the veterinarians are paid. A practice that puts its vets on salary rather than a cut of what they bill has removed the reason to sell you things your animal does not need. Ask for a written estimate, and ask which items are necessary and which are optional, and watch whether the vet treats that as a fair question or an irritation. The good ones are still out there. They have usually kept the same owner for years, they do not rush you, and they will talk plainly about money. That kind of clinic is worth driving past three corporate ones to reach.

Step back far enough and the veterinary story is one limb of something larger. The same Mars that owns your clinic and the lab it sends bloodwork to also makes Pedigree, Whiskas, Royal Canin, and Iams. Petcare is the single largest division inside Mars, bigger than the candy, and it accounted for 59% of the company's sales in 2023.

The food aisle has been consolidated by the same handful of conglomerates that took the clinics: Mars, Nestlé, General Mills, and a few others. The brands that look like spirited independents on the shelf mostly answer to one of them. You eat a tiny fraction of any single food company's output across a week. Your dog may eat one company's product, exclusively, for its entire life. That is a separate essay, and it is coming soon.